Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab versus secukinumab for moderate-to-severe plaque psoriasis
ChiCTR2400094794Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in plaque psoriasis comparing Vunakizumab group with Secukinumab group (2 arms). Primary endpoint: Median time to PASI 75. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
vunakizumabsecukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2400094794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094794.